Celgene (CELG), Sanofi (SNY), Stryker (SYK) Execs Charged in Insider Trading Ring
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Join SI Premium – FREE
Several notable pharma have had executives charged with insider trading, though stocks have seen little in the way of reaction as of yet.
According to data out today, the insider-trading ring amon execs from Celgene (Nasdaq: CELG), Sanofi (NYSE: SNY), and Stryker (NYSE: SYK) generated about $1.4 million in illicit profit, according to the U.S attorney in New Jersey. The U.S. SEC charged the men, along with Lazorchak's friend James Deprado, but said illicit profits were somewhere around $1.7 million.
Involved in the ring were:
* Celgene director of financial reporting John Lazorchak;
* Mark Cupo of Sanofi;
* Mark Foldy at Stryker;
* Lazorchak's friend Michael Pendolino;
* Lawrence Grum; and
* Michael Castelli.
According to data out today, the insider-trading ring amon execs from Celgene (Nasdaq: CELG), Sanofi (NYSE: SNY), and Stryker (NYSE: SYK) generated about $1.4 million in illicit profit, according to the U.S attorney in New Jersey. The U.S. SEC charged the men, along with Lazorchak's friend James Deprado, but said illicit profits were somewhere around $1.7 million.
Involved in the ring were:
* Celgene director of financial reporting John Lazorchak;
* Mark Cupo of Sanofi;
* Mark Foldy at Stryker;
* Lazorchak's friend Michael Pendolino;
* Lawrence Grum; and
* Michael Castelli.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SEC accuses ex-BofA senior banker Satsky of insider trading - Bloomberg
- Elroy Air wins $46M U.S. Army contract for cargo drone system
- MicroCloud Hologram acquires 140,268 MicroStrategy shares via structured note
Create E-mail Alert Related Categories
Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
